How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800β$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
Most people regain significant weight after stopping Ozempic. Here is what the STEP 4 trial shows and how to slow regain as much as possible.
Stopping Ozempic typically leads to weight regain β and the STEP 4 clinical trial quantified exactly how much. This is the most important fact to understand before deciding whether, when, and how to stop semaglutide treatment.
It is not a personal failing. It is the predictable biology of removing a hormone signal from a system that was relying on it.
The STEP 4 trial enrolled participants who had already completed 20 weeks on semaglutide 2.4 mg and had lost an average of 10.6% of body weight. At week 20, participants were randomised to either continue semaglutide or switch to placebo.
At week 68 (48 weeks after randomisation):
Most of the weight loss was reversed within 12 months of stopping. The regain was not gradual and mild β it was substantial and consistent.
When semaglutide is removed from the system, every mechanism it was maintaining reverses:
Appetite returns: The hypothalamic satiety signalling that semaglutide sustained disappears. Hunger and food cravings return to pre-treatment levels because the hormone driving them (or rather, blocking them) is gone.
Gastric emptying speeds up: Food moves through the stomach faster, reducing meal-time satiety. People feel hungry sooner after eating.
Insulin response changes: The improved insulin secretion pattern returns to baseline. Blood sugar cycling may increase, driving carbohydrate cravings.
Defended weight set-point reasserts: The body's homeostatic regulation of weight β which the body effectively defends through appetite and metabolism β targets the pre-treatment weight, not the new lower weight.
In STEP 4, most of the regain occurred within the first six months after stopping. The speed of regain reflects how quickly the appetitive hormones return to pre-treatment levels. Because semaglutide has a one-week half-life, it is substantially cleared from the body within four to five weeks of the last dose.
After clearance, appetite rebounds relatively quickly. The behavioural changes from treatment β learned smaller meals, less frequent snacking β persist longer, which is why regain in the first months post-stop is typically slower than full appetite return would suggest. Over time, as the new habits erode, regain accelerates.
Complete prevention of regain after stopping is not currently achievable for most patients. Slowing it is achievable:
Maintain high protein intake: At least 1.2 to 1.6 grams of protein per kilogram of body weight. Protein preserves lean mass and has the strongest natural satiating effect through both central and gut mechanisms.
Continue resistance training: Preserving lean mass through resistance exercise supports resting metabolic rate and reduces the relative proportion of regained weight that is fat.
Track food intake: The awareness and structure of tracking helps maintain portion control after the automatic appetite suppression from semaglutide ends.
Limit ultra-processed food: Re-exposing the food reward system to highly palatable processed foods accelerates the return of overeating behaviour. Structured whole-food eating during and after treatment supports slower regain.
Consider step-down rather than abrupt stop: Some physicians reduce dose gradually rather than stopping abruptly. Whether this meaningfully slows regain compared to abrupt cessation has limited evidence, but the rationale is sound.
For some patients, stopping is the right choice despite expected regain: during planned pregnancy, when cost is prohibitive and the alternatives have been exhausted, or when the weight already lost has achieved the primary health goal and maintenance through lifestyle change seems achievable.
The METASLIM 8-week physician-guided program is designed as a structured time-limited course, with the physician guidance built in specifically to support the establishment of habits during the program period that extend benefit after it ends.
METASLIMβ’ is a physician-guided GLP-1 sublingual program β injection-free appetite support, designed for sustainable weight loss.
The majority of patients regain significant weight after stopping, as shown by the STEP 4 trial. A minority maintain more of their weight loss through sustained lifestyle changes made during treatment. The proportion who maintain is higher among those who made significant dietary and exercise changes during the treatment period.
Most regain occurs within the first 12 months after stopping, with the first six months showing the most rapid return. The rate of regain reflects how quickly appetite returns to pre-treatment levels, which is typically weeks to months after the last dose.
Yes. There is no evidence that stopping and restarting reduces effectiveness. Many patients restart after a period off due to cost, pregnancy, or other reasons, and regain similar appetite suppression and weight loss response as on first treatment.
High protein at every meal (eggs, fish, legumes, dairy), abundant vegetables for fibre and satiety, limited ultra-processed food, and consistent meal timing. The goal is to maximise natural satiety signals to partially replace what semaglutide was providing.
If you were using Ozempic for diabetes management, blood glucose control will likely worsen after stopping, as the insulin secretion and glucagon suppression that Ozempic provided are removed. Discuss blood glucose monitoring and potential medication adjustment with your physician before stopping.
Not reliably. The only proven prevention for post-Ozempic weight regain is continuing the medication. Behavioural and dietary strategies slow regain but do not prevent it in most people. This is why clinical guidelines increasingly treat GLP-1 agonists as long-term medications rather than finite treatment courses. The regain after stopping Ozempic is one of the most discussed challenges in obesity medicine. It reflects what was not understood about obesity for most of the twentieth century: it is a hormonally regulated chronic condition, not a lifestyle failure. Removing the treatment removes the management. The appropriate response is to plan for continuation, not to be surprised by the biology. *This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.*